The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities

Episodes

Considerations for Drug Products that Contain Nanomaterials
15 mai· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Considerations for Drug Products that Contain Nanomaterials
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
Using Bayesian statistical approaches to advance our ability to evaluate drug products
18 août 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Using Bayesian statistical approaches to advance our ability to evaluate drug products
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
Episodes manquant?

Cliquez ici pour raffraichir la page manuellement.
Insights About the FDA/EMA Parallel Scientific Advice Program for Complex Generic/Hybrid Drug Products
11 juil. 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Insights About the FDA/EMA Parallel Scientific Advice Program for Complex Generic/Hybrid Drug Products
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
10 avril 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
7 févr. 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
29 sept. 2022· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
An FDA Self-Audit of Continuous Manufacturing for Drug Products
28 juin 2022· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
The Key Elements of Being “Recall-Ready”
20 avril 2022· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
A voluntary recall is an action taken by a company to correct a violative product or remove it from the market.
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
The ABCs of Product Specific Guidances
3 sept. 2021· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Product-specific guidances (or PSGs for short) describe the Agency's current thinking on the evidence needed to demonstrate that a generic drug is therapeutically equivalent to the corresponding reference listed drug (RLD) product.
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
Improving Regulatory Communication via the CDER NextGen Portal
19 déc. 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
Abbreviated Approval Pathways for Drug Product: 505(b)(2) or ANDA?
19 sept. 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Abbreviated Approval Pathways for Drug Product: 505(b)(2) or ANDA? | September 19, 2019 Issue
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
Research Investigational New Drug Applications – What You Need To Know
25 juin 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
FDA recently released an update to clarify when ‘Research’ vs. ‘Commercial’ should be selected on FDA Form 1571, and thus when electronic common technical document or “eCTD” requirements would apply for an investigational new drug or “IND” application.
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
Competitive Generic Therapies
23 mai 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Competitive Generic Therapies May 23, 2019 Issue
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard
FDA Modernizes Clinical Trials with Master Protocols
26 févr. 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
"FDA Modernizes Clinical Trials with Master Protocols" February 26, 2019 Issue
- Écouter Écoute encore Continuer Écoutez...
- Écoutez plus tard Écoutez plus tard

Episodes

Considerations for Drug Products that Contain Nanomaterials

Using Bayesian statistical approaches to advance our ability to evaluate drug products

Insights About the FDA/EMA Parallel Scientific Advice Program for Complex Generic/Hybrid Drug Products

The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development

FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds

An FDA Self-Audit of Continuous Manufacturing for Drug Products

The Key Elements of Being “Recall-Ready”

The ABCs of Product Specific Guidances

Improving Regulatory Communication via the CDER NextGen Portal

Abbreviated Approval Pathways for Drug Product: 505(b)(2) or ANDA?

Research Investigational New Drug Applications – What You Need To Know

Competitive Generic Therapies

FDA Modernizes Clinical Trials with Master Protocols